Woulgan (yeast beta-glucan) / ArcticZymes - LARVOL DELTA

Beta-Glucans in Biotechnology: A Holistic Review with a Special Focus on Yeast. (PubMed, Bioengineering (Basel)) - "Finally, this review explores the therapeutic potential of yeast-derived β-glucans, focusing on their role in immunomodulation and metabolic regulation and their emerging applications in biomedicine, functional foods, and industrial formulations. By synthesizing recent advancements, this work provides insights into the expanding utilization of yeast β-glucans and their potential for future biotechnological developments."

Journal • Review • Immunology

A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy. (ASCO 2023) - P1a | "5 US sites will participate. Clinical trial information: NCT04834778."

Clinical • Combination therapy • Metastases • P1 data • Gastrointestinal Cancer • Immune Modulation • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CD40

Conversion of Mixed Waste Food Substrates by Carotenogenic Yeasts of Rhodotorula sp. Genus. (PubMed, Microorganisms) - "The results show that both strains were able to produce more than 18 g of biomass per litre of media with a high content of carotenoids (10.757 ± 1.007 mg/g of CDW in R. kratochvilovae and 10.514 ± 1.520 mg/g of CDW in R. toruloides, respectively). The overall results prove that combining different waste substrates is a promising option for producing yeast biomass enriched with carotenoids, lipids, and beta-glucans."

Journal

A multicenter, open-label, phase 2 study of odetiglucan (IMPRIME PGG) and pembrolizumab in patients with metastatic breast cancer (mBCA) who have progressed through prior hormonal therapy. (ASCO 2022) - P2 | "in collaboration with Merck & Co. ̃25 US sites will participate."

Clinical • P2 data • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Immunology • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

Immunomodulating Effects of Fungal Beta-Glucans: From Traditional Use to Medicine. (PubMed, Nutrients) - "In addition to these developments related to food uses of beta-glucan-containing supplements, beta-glucans could also hold a novel position in Western medicine as the concept of trained immunity is relatively new and has not been investigated to a large extent. These innovative concepts, together with the emerging success of modern immunological and biotechnological methods, suggest that fungal glucans may play a promising role in both perspectives, and that there are possibilities for traditional medicine to provide an immunological application in both medicine and nutrition."

Journal • Review • Immune Modulation • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Analysis of the proteins secreted by Trichoderma harzianum P49P11 under carbon-limited conditions. (PubMed, J Proteomics) - "As far as we know, this is the first work about the continuous synthesis of enzymes under carbon-limited conditions suggesting that different easily assimilated carbon sources can be used to generate different enzymatic cocktails. Each enzyme or uncharacterized protein suggested by shotgun proteomics has the potential to become a promising product for biotechnological applications."

Journal

Evaluation of Woulgan in Diabetic Foot Ulcer (clinicaltrials.gov) - P4; N=62; Completed; Sponsor: Biotec Pharmacon ASA; Recruiting ➔ Completed; Trial completion date: Dec 2018 ➔ Apr 2019; Trial primary completion date: Oct 2018 ➔ Dec 2018

Trial completion • Trial completion date • Trial primary completion date